Back to Peptides
Oxytocin
Neuroprotective & Cognitive EnhancersOxytocin is a nonapeptide hormone that promotes uterine contraction, lactation, and emotional bonding. Intranasal oxytocin is under investigation for its effects on social cognition, emotional regulation, and conditions like autism and anxiety. It modulates brain circuits related to trust, fear, and empathy.
Reconstitute
3 mL BAC + 5mg vial
17 mcg/unit
Daily Range
12–48 IU Intranasal
Varies; often 2–3 times daily for behavioral use
Standard Dose
24 IU
Cycle
4–8 weeks
then reassess
Oxytocinbonding hormoneintranasalsocial cognitionautism
Dosing & Reconstitution Guide
In research, intranasal doses range from 20–40 IU. These are used in controlled trials and are not approved for elective or over-the-counter applications. While FDA-approved in clinical contexts (e.g., labor induction), oxytocin as a research compound is not approved for off-label or cognitive enhancement use
Standard / Gradual Approach
5mg VialstandardPhaseDoseVolume
Weeks 1–2100 mcg6 units (0.06 mL)
Weeks 3–4200 mcg12 units (0.12 mL)
Weeks 5–6300 mcg18 units (0.18 mL)
Weeks 7–8400 mcg24 units (0.24 mL)
Weeks 9–12500 mcg30 units (0.30 mL)
Standard / Gradual Approach
10mg VialstandardPhaseDoseVolume
Weeks 1–2100 mcg3 units (0.03 mL)
Weeks 3–4200 mcg6 units (0.06 mL)
Weeks 5–6300 mcg9 units (0.09 mL)
Weeks 7–8400 mcg12 units (0.12 mL)
Weeks 9–12500 mcg15 units (0.15 mL)
Protocol Summary
Intranasal: Varies; often 2–3 times daily for behavioral use · Dose range 12–48 IU with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
Intranasal
Apply 1–2 sprays per nostril up to 3x daily. Use in 5-on/2-off cycles or as needed for social and emotional regulation.
🧪 Quick Start
Vial Size
5 mg
BAC Water
3 mL
Concentration
1.67 mcg/unit
Starting Dose
100 mcg (6 units (0.06 mL))
Maintenance Dose
500 mcg (30 units (0.30 mL))
Potential Benefits & Use Cases
Oxytocin is only approved for specific medical indications. The information here refers to research and investigational contexts.
Increases trust, social bonding, and reduces anxiety in social situations (limited human data)
Reduces caloric intake by ~122 kcal at test meals, preferentially reducing fat consumption (human trial)
Increases fat oxidation and elevates cholecystokinin (human trial)
Demonstrates analgesic effects — significant reduction in heat pain intensity and unpleasantness (human trial)
Shows anxiolytic and mood-modulating properties without significant side effects in short-term studies (human trial)
Shows promise as adjunctive therapy for PTSD, depression, and addiction (human trial — mixed)
Placebo-like safety profile at 18–40 IU intranasal (human trial)
Clinical data Strong preclinical Limited data
Mechanism of Action
→Binds to oxytocin receptors (OXTR) in the uterus and brain
→Triggers intracellular calcium release, causing muscle contraction
→Activates regions of the brain linked to empathy, trust, and bonding
→Modulates social cognition and fear response in the amygdala
Lifestyle & Optimization
timing
Consistent injection timing and site rotation.
diet
Balanced nutrient-dense diet.
exercise
Regular exercise.
sleep
Sleep 7–9 hours.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Study TitleType
Cleveland Clinic — Oxytocin overviewReference
Side Effects & Safety
Common Side Effects
• Nasal irritation and discomfort (14% in trials)
• Headache (10%), dry mouth, runny nose
• Burning sensation in nose (10%), lightheadedness
• Irritability (9%), tiredness (7%)
🧮 Dose Calculator
Concentration
16.7
mcg/unit
Draw Volume
30
units (0.300 mL)
For a 500 mcg dose, draw 30 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
Limited CNS effects; used for uterotonic purposes only
Oral Administration
Poor due to degradation in the GI tract
Intranasal
High bioavailability for CNS access via olfactory and trigeminal pathways
Half-Life
3–5 minutes in peripheral blood
Degradation
Cleared rapidly via hepatic and renal enzymatic breakdown
Tissue Specificity
Acts centrally in the hypothalamus and limbic system, peripherally in uterus and mammary tissue
⚗️
Peptide Details
Molecular Weight
1007.19
Formula
C43H66N12O12S2
Sequence
CYIQNCPLG
⚖️
Legal Status & Regulatory
RegionStatus
FDAApproved
EUApproved
AustraliaApproved
CanadaApproved
Storage Instructions
Lyophilized (Powder)
freeze at −20 °C (−4 °F) or refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 28–30 days
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); stable for up to 28–30 days with bacteriostatic water